UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
|X| QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the quarterly period ended: May 31, 2006
OR
|_| TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT OF 1934
For the transition period from ________________ to __________________________
Commission File No. 0-26057
BIOPHAN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Nevada 82-0507874
--------------------------------- ------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
150 Lucius Gordon Drive, Suite 215
West Henrietta, New York 14586
(Address of principal executive offices) (Zip Code)
(585) 214-2441 (Registrant's
telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes |X| No |_|
Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check
one).
Large Accelerated Filer |_| Accelerated Filer |X| Non-Accelerated Filer | |
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).
Yes |_| No |X|
Indicate the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date.
Class outstanding as of July 5, 2006 - Common Stock, $.005 par value -
82,809,199 shares
INDEX
Page
Number
PART I FINANCIAL INFORMATION
ITEM 1. Financial Statements
Condensed Consolidated Balance Sheets, May 31, 2006
(Unaudited) and February 28, 2006 1
Condensed Consolidated Statements of Operations, Three Months
Ended May 31, 2006 and 2005 (Unaudited), and from August 1,
1968 (Date of Inception) through May 31, 2006 (Unaudited) 2
Condensed Consolidated Statements of Cash Flows, Three Months
Ended May 31, 2006 and 2005 (Unaudited) and from August 1, 1968
(Date of Inception) through May 31, 2006 (Unaudited) 3
Notes to Condensed Consolidated Financial Statements 6
ITEM 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations 10
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 15
ITEM 4. Controls and Procedures 15
PART II. OTHER INFORMATION 16
ITEM 1. Legal Proceedings 16
ITEM 1A. Risk Factors 16
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 16
ITEM 3. Defaults Upon Senior Securities 16
ITEM 4. Submission of Matters to a Vote of Security Holders 16
ITEM 5. Other Information 17
ITEM 6. Exhibits 17
SIGNATURES 18
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED BALANCE SHEETS
May 31, February 28,
2006 2006
------------ ------------
ASSETS (Unaudited)
Current assets:
Cash and cash equivalents $ 715,309 $ 1,441,178
Accounts receivable 69,010 162,558
Stock subscriptions receivable 1,700,000 --
Due from related parties 148,675 41,577
Prepaid expenses 85,094 131,633
Other current assets 58,677 81,048
------------ ------------
Total current assets 2,776,765 1,857,994
Property and equipment, net 102,207 91,434
Other assets:
Intellectual property rights, net of amortization 929,522 943,165
Investment in New Scale Technologies, Inc. 100,000 100,000
Investment in and advances to Myotech, LLC 12,106,730 11,767,062
Security deposit 3,800 3,800
Deferred tax asset, net of valuation allowance of
$8,539,000 and $7,560,000, respectively -- --
------------ ------------
13,140,052 12,814,027
------------ ------------
$ 16,019,024 $ 14,763,455
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses $ 1,309,050 $ 1,081,960
Line of credit - related party, net of discount
of $1,387,342 and $1,323,921, respectively 3,542,658 1,476,079
Notes payable 47,258 --
Due to related parties 29,235 27,114
Deferred revenues 270,833 520,833
------------ ------------
Total current liabilities 5,199,034 3,105,986
Minority interest 24,464 69,543
Stockholders' equity:
Common stock $.005 par value
Authorized 125,000,000 shares
Issued and outstanding 82,809,199 and
81,805,243 shares, respectively 414,046 409,026
Additional paid-in capital 45,830,060 42,979,203
Deficit accumulated during the
development stage (35,448,580) (31,800,303)
------------ ------------
10,795,526 11,587,926
------------ ------------
$ 16,019,024 $ 14,763,455
============ ============
See Notes to Condensed Consolidated Financial Statements.
1
BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Period from
August 1, 1968
Three Months Ended (date of
---------------------------- inception) to
May 31, 2006 May 31, 2005 May 31, 2006
------------ ------------ ------------
Revenues:
Development payments $ -- $ -- $ 300,000
License fees 250,000 -- 729,166
Consulting fees 94,922 -- 435,617
------------ ------------ ------------
344,922 -- 1,464,783
Operating expenses:
Research and development 1,542,852 1,599,742 13,883,657
General and administrative 1,930,508 1,895,984 19,591,147
Write-down of intellectual property rights -- -- 530,000
------------ ------------ ------------
3,473,360 3,495,726 34,004,804
------------ ------------ ------------
Operating loss (3,128,438) (3,495,726) (32,540,021)
Other income(expense):
Interest expense (303,473) -- (3,175,262)
Interest income 6,343 2,749 135,491
Equity loss on investment (335,331) -- (558,323)
Other income 112,622 83,138 843,978
Other expense -- -- (65,086)
------------ ------------ ------------
(519,839) 85,887 (2,819,202)
------------ ------------ ------------
Loss from continuing operations (3,648,277) (3,409,839) (35,359,223)
Loss from discontinued operations -- -- (89,357)
------------ ------------ ------------
Net loss $ (3,648,277) $ (3,409,839) $(35,448,580)
============ ============ ============
Loss per common share - basic and diluted $ (0.04) $ (0.05)
============ ============
Weighted average shares outstanding 81,816,844 74,417,378
============ ============
See Notes to Condensed Consolidated Financial Statements.
2
BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Period from
Three Months Ended August 1, 1968
May 31, (date of
---------------------------- inception) to
2006 2005 May 31, 2006
------------ ------------ ------------
Cash flows used for operating activities:
Net loss $ (3,648,277) $ (3,409,839) $(35,448,580)
Adjustments to reconcile net loss to net cash
used in operating activities:
Amortization of intellectual property rights 13,643 13,643 68,216
Depreciation 8,757 9,412 144,018
Loss on disposal of equipment -- 1,505 1,505
Realized and unrealized losses on marketable securities -- -- 66,948
Accrued interest on note converted to common stock -- -- 31,504
Amortization of interest on convertible notes payable -- -- 1,050,950
Write-down of intellectual property rights -- -- 530,000
Amortization of discount on payable to related party 209,524 -- 1,356,088
Issuance of common stock for services -- -- 406,948
Issuance of common stock for interest -- -- 468,823
Grant of stock options for services 580,954 1,462,082 7,144,532
Expenses paid by stockholder -- -- 2,640
Equity loss on investment 335,331 -- 558,323
Minority interest (45,079) 76,493 24,464
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable 93,548 -- (69,010)
(Increase) decrease in due from related parties (107,098) 29,906 (148,675)
(Increase) decrease in prepaid expenses 46,539 15,839 (85,094)
(Increase) decrease in other current assets 22,372 5,910 (17,338)
(Increase) decrease in security deposits -- (867) (3,800)
Increase (decrease) in accounts payable and
accrued expenses 227,090 (5,045) 1,052,495
Increase (decrease) in due to related parties 2,121 -- (14,261)
Increase (decrease) in deferred revenues (250,000) -- 270,833
------------ ------------ ------------
Net cash used in operating activities (2,510,575) (1,800,961) (22,608,471)
Cash flows used for investing activities:
Purchases of property and equipment (19,530) (23,255) (246,708)
Sales of marketable securities -- -- 2,369,270
Purchase of investment -- -- (100,000)
Investment in and advances to Myotech, LLC (675,000) -- (2,326,585)
Cash paid for acquisition of Biophan Europe,
net of cash received of $107,956 -- -- (258,874)
Purchases of marketable securities -- -- (2,436,218)
------------ ------------ ------------
Net cash provided by (used in) investing activities (694,530) (23,255) (2,999,115)
See Notes to Condensed Consolidated Financial Statements.
3
BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended Period from
---------------------------- August 1, 1968
May 31, (date of
---------------------------- inception) to
2006 2005 May 31, 2006
------------ ------------ ------------
Cash flows provided by financing activities:
Proceeds of bridge loans -- -- 986,500
Loan from stockholder -- -- 143,570
Line of credit borrowing from related party, net of
discount 3,630,000 -- 8,480,950
Line of credit payments (1,500,000) -- (2,072,500)
Notes payable 47,258 -- (152,742)
Proceeds from sales of common stock 300,000 900,000 16,563,849
Exercise of options 1,978 112,541 647,266
Exercise of warrants -- -- 1,142,451
Swing profits -- 295,362 696,087
Deferred equity placement costs -- -- (112,536)
------------ ------------ ------------
Net cash provided by financing activities 2,479,236 1,307,903 26,322,895
------------ ------------ ------------
Net increase(decrease) in cash and equivalents (725,869) (516,313) 715,309
Cash and equivalents, beginning 1,441,178 753,288 --
------------ ------------ ------------
Cash and equivalents, ending $ 715,309 $ 236,975 $ 715,309
============ ============ ============
Supplemental schedule for cash paid for:
Interest $ 30,000 $ -- $ 39,800
============ ============ ============
Supplemental schedule of non cash investing and financing activities:
Allocation of proceeds from line of credit - related party
to beneficial conversion feature and warrants $ 272,945 $ -- $ 2,668,430
============ ============ ============
Common stock issued for subscription receivable $ 1,700,000 $ -- $ 2,750,000
============ ============ ============
Issuance of common stock upon conversion
of line of credit loans $ -- $ -- $ 1,978,450
============ ============ ============
Issuance of common stock for the acquisition of
a 35% interest in Myotech, LLC $ -- $ -- $ 10,338,468
============ ============ ============
Issuance of common stock in satisfaction of
accounts payable $ -- $ -- $ 134,000
============ ============ ============
See Notes to Condensed Consolidated Financial Statements.
4
BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended Period from
---------------------------- August 1, 1968
May 31, (date of
---------------------------- inception) to
2006 2005 May 31, 2006
------------ ------------ ------------
Liabilities assumed in conjunction with acquisition of 51% interest in
Biophan Europe and certain intellectual property rights:
Fair value of assets acquired $ 1,105,714
Cash paid (366,830)
Promissory note issued (200,000)
Restricted stock issued (134,000)
Payables incurred (226,500)
------------
Liabilities assumed $ -- $ -- $ 178,384
============ ============ ============
Issuance of common stock upon conversion
of bridge loans $ -- $ -- $ 1,142,068
============ ============ ============
Acquisition of intellectual property $ -- $ -- $ 425,000
============ ============ ============
Intellectual property acquired through issuance of
capital stock and assumption of related party payable $ -- $ -- $ 175,000
============ ============ ============
See Notes to Condensed Consolidated Financial Statements.
5
BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
May 31, 2006
INTERIM FINANCIAL STATEMENTS:
The condensed consolidated financial statements as of May 31, 2006 and for the
three months ended May 31, 2006 and 2005 are unaudited. However, in the opinion
of management of the Company, these financial statements reflect all
adjustments, consisting solely of normal recurring adjustments, necessary to
present fairly the financial position and results of operations for such interim
periods. The results of operations for the interim periods presented are not
necessarily indicative of the results to be obtained for a full year. These
unaudited condensed consolidated financial statements should be read in
conjunction with the audited consolidated financial statements and notes thereto
included in the Company's Annual Report on Form 10-K/A for the fiscal year ended
February 28, 2006.
BASIS OF CONSOLIDATION:
The consolidated financial statements include the accounts of Biophan
Technologies, Inc. ("Biophan"), its wholly owned subsidiaries, LTR Antisense
Technology, Inc.("Antisense") and Nanolution, LLC, ("Nanolution"), and its
majority owned subsidiaries Biophan Europe GmbH ("Biophan Europe"), and TE Bio
LLC ("TE Bio"), collectively referred to as the "Company". All significant
intercompany accounts and transactions have been eliminated in consolidation.
COMPANY HISTORY:
The Company was incorporated under the laws of the State of Idaho on August 1,
1968 and on January 12, 2000, changed its domicile to Nevada by merging into a
Nevada corporation, and on July 19, 2001, changed its name to Biophan
Technologies, Inc. From the inception of the current line of business on
December 1, 2000, the Company has not generated any material revenues.
Therefore, the Company is in the development stage and will remain so until the
realization of significant revenues. The Company's ability to continue in
business is dependent upon maintaining sufficient financing or attaining future
profitable operations.
PRINCIPAL BUSINESS ACTIVITIES:
The primary mission is to develop and commercially exploit technologies for
improving the performance, and as a result, the competitiveness of biomedical
devices manufactured by third party companies. The Company possesses
technologies for enabling biomedical devices, both implantable and those used in
diagnostic and interventional procedures, to be safe (do not harm the patient or
physician) and compatible (allow effective imaging of the device and its
surrounding tissue) with MRI (magnetic resonance imaging). The Company is also
developing technologies for improving MRI contrast agents; for improved drug
elution and drug delivery systems, including an MRI safe and image compatible
ceramic motor; a system for generating power for implantable devices from body
heat, and a series of implantable devices including an MRI-visible vascular
implants such as a vena cave filter, a heart valve and an occluder for the
treatment of atrial septal defects, a hole in the wall separating the left and
right chambers of he heart. The Company's first licensee for several of these
technologies is Boston Scientific (NYSE: BSX). The Company is also an owner of a
substantial minority interest, with rights to take a majority interest, in
Myotech, developers of the MYO-VAD, a cardiac assist device that does not
contact circulating blood and utilizes technology that has the potential to
become a standard of care in the device market for treating multiple types of
acute and chronic heart failure including congestive heart failure and sudden
cardiac arrest.
ACCOUNTING FOR STOCK- BASED COMPENSATION
The Company has a single stock-based compensation plan, entitled Biophan
Technologies, Inc. 2001 Stock Option Plan (the "Plan") which is stockholder
approved. The Plan provides for the granting of incentive and non-qualified
stock options and restricted stock to selected employees, the granting of
non-qualified options and restricted stock to selected consultants, directors,
and advisory board members. The Option Plan is administered by the Compensation
Committee of the Board and authorizes the grant of options or restricted stock
awards for 13,000,000 shares. The Compensation Committee determines which
eligible individuals are to receive options or other awards under the Plan, the
terms and conditions of those awards, the applicable vesting schedule, the
option price and term for any granted options, and all other terms and
conditions governing the option grants and other awards made under the Option
Plan. Non-employee directors also receive periodic option grants pursuant to the
automatic grant program in effect for them under the Plan. The Company's Board
of Directors has adopted a new 2006 Incentive Stock Plan, subject to stockholder
approval. If approved at the Annual Meeting of Stockholders on July 18, 2006,
the new plan would authorize 7,500,000 shares for issuance pursuant to various
types of stock-based awards.
6
Effective March 1, 2006, the Company adopted SFAS No. 123 (revised),
"Share-Based Payment" (SFAS 123(R)) utilizing the modified prospective approach.
Prior to the adoption of SFAS 123(R), we accounted for stock option grants to
employees and directors in accordance with APB Opinion No. 25, "Accounting for
Stock Issued to Employees" (the intrinsic value method) and adopted the
disclosure-only provisions of SFAS 123, "Accounting for Stock-Based
Compensation". Accordingly, employee compensation expense was recognized only to
the extent that the fair value of our common stock on the date of grant exceeded
the stock option exercise price.
Under the modified prospective approach, the Company applies the measurement
principles of SFAS 123(R) to new grants and to grants that were outstanding on
February 28, 2006 that are subsequently modified, repurchased or cancelled.
Compensation cost recognized in the first quarter of fiscal 2007 includes
compensation cost for all share-based payments granted prior to, but not yet
vested as of February 28, 2006, based on the grant-date fair value estimated in
accordance with the original provisions of SFAS 123, and compensation cost for
all share-based payments granted subsequent to February 28, 2006, based on the
grant-date fair value estimated in accordance with the provisions of SFAS
123(R). Prior periods were not restated to reflect the impact of adopting the
new standard.
As a result of adopting SFAS 123(R) on March 1, 2006, our net loss and basic and
diluted loss per share for the three months ended May 31, 2006, were $477,949
and $ 0.006 per share greater than if we had continued to account for
stock-based compensation under APB Opinion No. 25 for our stock option grants.
The following table illustrates the effect on operating results and per share
information had the Company accounted for stock-based compensation in accordance
with SFAS 123(R) for the three months ended May 31, 2005:
Net loss - as $(3,409,839)
reported
Add: Stock-based employee compensation
expense included in reported net loss,
net of related tax effects 1,339,000
Deduct: Total stock-based employee
compensation expense determined
under fair value based method for
all awards, net of related tax effects (2,155,000)
-----------
Net loss - pro forma $(4,225,839)
===========
Basic and diluted loss
per share - as reported $ (.05)
===========
Basic and diluted loss
per share - pro forma $ (.06)
===========
We use the Black-Scholes-Merton option pricing model to estimate the fair value
of stock-based awards with the following weighted-average assumptions for the
indicated periods:
Three months ended May 31, 2006 2005
---- ----
Expected volatility 119.7-121.8 87.8
Risk-free interest rate 4.6% 4.08%
Expected life of options (years) 5-10 years 9-10 years
Weighted-average grant-date fair value $1.46 $2.06
Expected dividends -0- -0-
The assumptions above are based on multiple factors, including historical
exercise patterns of employees in relatively homogeneous groups with respect to
exercise and post-vesting employment termination behaviors, expected future
exercising patterns for these same homogeneous groups and the implied volatility
of our stock price.
At May 31, 2006, there was $1,580,163 of unrecognized compensation cost related
to stock-based payments which is expected to be recognized over a
weighted-average period of 1.65 years.
7
The following table represents stock option activity for the three months ended
May 31, 2006:
Weighted-Average Weighted-Average
Number of Exercise Remaining
Shares Price Contract Life
--------- ---------------- ----------------
Outstanding options at beginning of period 9,594,020 $ .95
Granted 80,000 $ 1.44
Exercised (3,956) $ .50
Forfeited (92,000) $ 1.18
---------
Outstanding options at end of period 9,578,064 $ .95 7.23
========= ================ ================
Outstanding exercisable at end of period 6,759,314 $ .74 6.63
========= ================ ================
Shares available for future stock option grants to employees and others under
our 2001 Stock Option Plan were 247,982. At May 31, 2006, the aggregate
intrinsic value of shares outstanding was $3.9 million, and the aggregate
intrinsic value of options exercisable was $ 3.4 million. Total intrinsic value
of options exercised was $3,165 for the three months ended May 31, 2006.
The following table summarizes our nonvested stock option activity for the three
months ended May 31, 2006:
Number Weighted-Average
of Shares Grant-Date Fair Value
---------- ---------------------
Nonvested stock options at beginning of period 3,048,750 $ 1.31
Granted -- --
Vested 138,000 $ 1.53
Forfeited (92,000) $ 1.53
----------
Nonvested stock options at end of period 2,818,750 $ 1.29
==========
RECLASSIFICATION
For comparative purposes, certain amounts in the accompanying statement of
operations for fiscal 2006 have been reclassified to conform to the presentation
used for fiscal 2007. These reclassifications had no effect on previously
reported results of operations or accumulated deficit.
REVENUE RECOGNITION:
The Company earns and recognizes revenue under development agreements when the
phase of the agreement to which amounts relate is completed and the Company has
no further performance obligation. Completion is determined by the attainment of
specified milestones including a written progress report. Advance fees received
on such agreements are deferred until recognized.
The Company recognizes initial license fees over the term of the related
agreement. Revenue related to a performance milestone is recognized upon the
achievement of the milestone, as defined in the respective agreements.
The Company recognizes revenues from testing services and consulting fees as
services are performed.
8
STOCKHOLDERS' EQUITY
On May 27, 2005, the Company entered into a Stock Purchase Agreement with SBI
Brightline XI, LLC. The agreement provides a $30 million fixed price financing
for up to 10,000,000 shares at prices ranging from $2 to $4 a share. The sales
of stock must be taken in sequential traunches of 1 million shares each and the
financing agreement requires the shares to be registered for sale by SBI. There
are no resets, warrants, finder's fees or commissions associated with this
financing transaction. Registration of the shares for resale by SBI was
effective on May 18, 2006 and the Company elected to put the first traunche of 1
million shares at $2 per share on May 23, 2006. Of the total proceeds of
$2,000,000, $300,000 was received by May 31, 2006 and the balance was received
on June 7, 2006.
INVESTMENT IN MYOTECH LLC:
Effective November 30, 2005, we entered into a Securities Purchase Agreement for
the acquisition of an initial 35% interest in Myotech, LLC ("Myotech"), a New
York limited liability company, whereby we exchanged 4,923,080 shares of our
common stock, par value $.005, for 3,768,488 Class A (voting) units of Myotech.
Based upon the terms of the Securities Purchase Agreement, we are obligated to
purchase for cash consideration of $2.225 million an additional 811,037 Class A
units. We may elect to acquire up to an additional 3,563,097 Class A units for a
further cash consideration of up to $9.775 million, over a 24-month period,
which may result in the Company owning a majority interest in Myotech.
During the three month period ended February 28, 2006, Biophan provided
$1,185,000 of additional funding for 31,946 Class A units of Myotech.
During the three month period ended May 31, 2006, Biophan has provided $675,000
of additional funding toward the cash consideration of $2.225 million cited
above, for 246,045 Class A units of Myotech, which increased our ownership to
41.6%. Biophan has also provided an additional amount of funding since May 31,
2006 of $250,000, increasing our ownership to 42.0%. This acquisition is being
accounted for under the equity method. The Company's pro rata share of the
equity loss for the three months ended May 31, 2006 was $335,331.
The following is selected financial data for Myotech, LLC:
May 31, 2006
------------------
Total current assets $ 23,167
Noncurrent assets (1) 6,145,521
------------------
Total assets $ 6,168,688
==================
Current liabilities $ 482,647
Equity 5,686,041
------------------
$ 6,168,688
==================
Three Months
Ended May 31, 2006
------------------
Net loss from operations $ (842,372)
==================
Equity share of loss $ (335,331)
==================
----------
(1) Noncurrent assets includes 4,923,080 shares of Biophan common stock
received under the Securities Purchase Agreement. With a value at May 31,
2006 of $5,926,597.
9
LINE OF CREDIT AGREEMENT:
On January 24, 2006, we entered into a Line of Credit Agreement (the "Line of
Credit Agreement") with Biomed, a related party, pursuant to which Biomed has
committed to make advances to us, in an aggregate amount of up to $5,000,000.
Under the Line of Credit Agreement, advances may be drawn down in such amounts
and at such times as we determine upon 15 days prior notice to Biomed, except
that we may not draw down more than $1,500,000 in any 30-day period. Amounts
borrowed will bear interest at the rate of 8% per annum and are convertible into
shares of our Common Stock at the rate of $1.46 per share. Biomed's obligation
to lend to us under the Line of Credit Agreement expires on June 30, 2007, on
which date the entire amount borrowed by us (and not converted into shares of
our Common Stock) becomes due and payable. We are obligated to utilize the
entire credit facility. In connection with the establishment of the credit
facility under the Line of Credit Agreement, on January 24, 2006 we issued to
Biomed a Stock Purchase Warrant (the "Warrant") entitling Biomed to purchase up
to 1,198,630 shares of our Common Stock at an exercise price of $1.89 per share.
The Company recorded an additional discount of $272,945 on incremental
borrowings during the quarter of $2,650,000 due to the beneficial conversion
feature of the note. The discount is being amortized as additional interest
expense over the term of the note. During the quarter ended May 31, 2006
amortization of the discount on the note resulted in a non-cash interest expense
of $209,524. Biomed's purchase rights under the Warrant expire on January 23,
2011. The Company is required to make its best efforts to register the common
stock underlying the warrants and it is not required to settle any part or all
of the instruments with cash. Accordingly, these instruments are classified as
equity. The balance of borrowings on the line was $4,430,000 at May 31, 2006.
The fair value of the note approximates the principal value of the note.
On May 27, 2005, we entered into a Line of Credit Agreement with Biomed, a
related company, whereby Biomed agreed to provide a line of credit facility of
up to $2 million. Borrowings under the line bear interest at 8% per annum, are
payable on demand after August 31, 2006 and are convertible, at Biomed's
election into the Company's common stock at 90% of the average closing price for
the 20 trading days preceding the date of borrowings under the line. In June
2005, the Company borrowed the entire $2 million under the line in two separate
draws of $1 million each and, in accordance with the agreement, Biomed received
warrants to purchase 500,000 shares of the Company's common stock at an exercise
price of 110% of the average closing price for the 20 trading days preceding the
date of execution of the credit agreement. The Company recorded a discount on
the borrowings of $958,160 due to the beneficial conversion feature of the note
as well as for the value of the warrants. The discount was amortized as
additional interest expense over the term of the note and has been fully
amortized as of November 30, 2005. On August 31, 2005, Biomed elected to convert
$1 million of the note plus accrued interest into 480,899 shares of common stock
at which time, the remaining discount related to the $1 million portion of the
loan was fully expensed. On October 7, 2005, we repaid $500,000 of principal and
all accrued interest on the loan. The balance of borrowings on the line was
$500,000 at May 31, 2006.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
Our primary mission is to develop and commercially exploit technologies for
improving the performance, and the corresponding competitiveness, of biomedical
devices manufactured by third party companies. We do not currently employ our
own manufacturing or distribution channels but rather rely on relationships with
sub-contractors and/or partner companies. We develop technology protected by
strong intellectual property targeted at specific markets within the medical
technology sector.
COMPANY BUSINESS
We are a technology development company with a strong focus on solving
real-world technical challenges facing the medical device industry. When
selecting a market opportunity to address, we have generated a wide range of
potential technical solutions. Each technical solution we pursue is
well-protected by intellectual property to ensure that we have the capability to
effectively market our technologies. Whenever practical, we attempt to develop
and patent multiple solutions for any given technology requirement. This is done
both to strengthen our position against competitors, and to be in a position to
offer multiple manufacturers alternative solutions, such as for MRI safety of
pacemakers, or MRI visibility of Vascular stents, as we introduce our
technologies to the market.
This approach has resulted in the development of a range of core technologies,
in various related segments of the medical device market. We are aggressive in
development and defense of our intellectual property assets and have an
intellectual property portfolio several times the size of many comparable sized
companies.
10
Over the past quarter, we have:
o Continued to develop and market our technology to solve the problems
of MRI safety that prevent people with pacemakers,
cardio-defibrillators, neurostimulators, pain control devices,
pumps, and virtually any implanted or interventional device with
elongated metal leads to undergo MRI;
o Hosted the first Biophan Symposium on MRI Safety at the SMIT2006
Conference in Pebble Beach, CA, where we presented issues of MRI
Safety. Presentations were given by the FDA and the NIH, validating
the issues of MRI heating of medical devices which have been the
subject of some industry debate. The sessions were attended by
Medtronic, Boston Scientific, Guidant, and St. Jude, and workshops
were conducted between several of these companies, Biophan, and the
FDA on how to research and define test methods for measuring MRI
safety of medical implants under MRI, which will be required to
eventually remove the current contraindication of these devices.
o Held meetings with representatives of multiple medical device
companies concerning Biophan's solutions for MRI safety, and entered
into currently ongoing negotiations with several of these companies
in which we have responded to requests for pricing for exclusive and
co-exclusive licensing options;
o Recognized over $344,000 in revenue from licensing, MRI testing, and
consulting to the industry. We expect to recognize additional
revenue from these transactions in the next several quarters.
o Supported development of a new cardiac assist device, the MYO-VAD,
through our relationship with Myotech LLC. The MYO-VAD is a
life-saving device that provides benefits and competitive advantages
not possible with other cardiac assist devices. In the past, this
technology has saved human lives and holds tremendous promise for
the treatment of multiple forms of acute and chronic heart failure.
o Continued optimization of our technology to improve stents so they
can be imaged with MRI to detect the presence of restenosis
(blockage) after implantation; this technology is licensed
exclusively to Boston Scientific (NYSE:BSX), who has rights to
enforce and/or sub-license the technology to third parties.
11
o Continued development of an MR image compatible vena cava filter,
which allows MR imaging of blood clots that may be present in the
filter to ensure safe removal of the device. We are also developing
a heart valve which can be imaged and also implanted under MRI and
an occluder device to treat atrial septal defects a hole in the
septum between the left and right atria which will be the first
occluder to be visible as well as implantable under MRI.
o We have made progress on our other technology areas including drug
elution and drug delivery systems with "active release" using
non-invasive or minimally invasive activation; a power system to
generate electricity from body heat, and improved contrast agents.
LICENSING AND JOINT VENTURE STRATEGY
BOSTON SCIENTIFIC LICENSE
On June 30, 2005, we entered into a licensing agreement with Boston Scientific
Scimed, Inc. The agreement provides Boston Scientific with the right to use
Biophan's MRI safety and image compatibility technology in a broad range of
exclusive and non-exclusive product areas at royalty rates of 3% to 5%. The
exclusive product area includes vascular implants, and RF ablation catheters,
and the non-exclusive product area covers a broad array of medical devices
including MRI safe pacemakers, defibrillators, neurostimulators, guidewires and
catheters.
Boston Scientific has the right to sub-license the exclusive product areas to
third parties, with Biophan and Boston Scientific to share all proceeds from
these parties. The agreement also provides for milestone payments to Biophan for
specific product areas which may be as high as several million dollars per
product. In addition, the agreement required Boston Scientific to make an
initial upfront payment to Biophan of $750,000, which was made on the closing of
the agreement and is being amortized over twelve months and to make annual
minimum royalty and potentially substantial annual earned royalty payments; and
receive a right of first negotiation on new technologies acquired by Biophan in
the fields of MRI safety and image compatibility. The initial $750,000 payment
was made on August 2, 2005 and will be recognized as revenue over the next 12
months. Accordingly, one quarter of the $750,000, or $187,500 was recorded as
revenue in the current quarter ended May 31, 2006.
In December, 2005, we received $250,000 for the first annual minimum payment
under our license. The agreement calls for milestone payments upon achievement
of significant project milestones, and requires payment of royalties for
products sold incorporating our technologies. Boston Scientific has sublicensing
rights to certain technologies, sharing revenue with Biophan, and other product
lines will revert to Biophan in the event of non-performance. The agreement
includes non-exclusive rights to our technology for making pacemakers,
defibrillators and neurostimulators safe and image compatible for use with MRI,
and extends to any companies in which they acquire a 50% or greater interest. As
a result, both Guidant, and Advanced Bionics, acquired by Boston Scientific
since we closed our license with them, are eligible to use our technology in
their products. This agreement is available as an Exhibit to our 10-Q for the
quarter ended August 31, 2005, as amended on January 9, 2005.
Revenue from this $250,000 payment is being recognized over 12 months.
Accordingly, for the three months ended May 31, 2006, the Company recorded
$62,500 in revenue from this payment.
ACQUISITION OF INTELLECTUAL ASSETS
We currently have an overall estate of 237 patents issued and pending. The total
includes 176 U.S. patents licensed, issued, allowed or pending (56 of which have
been issued) and 61 international patents or applications in process.
We believe that a strong and broad intellectual property portfolio is vital to
our ability to achieve and maintain royalties and product sales to major
industrial partners across our product lines.
These technologies cover a broad array of capabilities, with primary focus on
our core businesses of:
o making medical devices safe for use with MRI, as many are
contraindicated, including pacemakers, defibrillators and
neurostimulators
o making devices such as stents visible under MRI so that they can be
non-invasively examined for in-stent restenosis. Today an invasive
angiogram procedure is required. We believe that non-invasive
imaging of stents is a feature which can move market share between
otherwise competitive devices.
12
The technologies allowing visualization of implants have been developed at
Biophan, and with technology partners under exclusive license, including aMRIs
Patents GmbH in Germany (via an exclusive license); Aachen Resonance in Germany
(via an exclusive license); and Nanoset, LLC in the U.S. (via an exclusive
license). Biophan holds both sub-licensing and enforcement rights (rights to
litigate) under these agreements. The patents include those licensed from
Nanoset, LLC. Nanoset's technology can be used to reduce image artifacts caused
by implantable and interventional medical devices.
The patent total also includes those licensed as part of the Biophan Europe
acquisition whereby we obtained worldwide exclusive rights to a significant
patent portfolio totaling fifteen issued and pending patents covering critical
capabilities needed by the medical industry as the use of MRI interventional
medicine and MRI diagnostics for examination of stents and other implants
becomes standard medical procedure.
On an ongoing basis we review our patent portfolio to ensure we are protecting
our innovations and new discoveries in those strategic areas of our business
where we believe the medical device industry is heading. To ensure the
continuing value of our intellectual assets, we intend to aggressively defend
our patents and licensed technology, both domestically and abroad. Additionally,
our license agreement with Boston Scientific gives them enforcement rights in
the areas of our business which are exclusive to them. They also have
sub-licensing rights, should they elect to allow one of their competitors to
enjoy access to those technologies.
LIQUIDITY
As further described under the heading "Line of Credit Agreement" in Notes to
Condensed Consolidated Financial Statements, our affiliate Biomed Solutions,
LLC, a related company, provided us with a $5 million Line of Credit. Under the
Line of Credit agreement, advances may be drawn down in such amounts and at such
times as we determine upon 15 days prior notice to Biomed, except that we may
not draw down more than $1,500,000 in any 30-day period. Amounts borrowed will
bear interest at the rate of 8% per annum and are convertible into shares of our
Common Stock at the rate of $1.46 per share. Biomed's obligation to lend to us
under the line of credit agreement expires on June 30, 2007, on which date the
entire amount borrowed by us (and not converted into shares of our Common Stock)
becomes due and payable. We are obligated to utilize the entire credit facility.
at terms we believe to be competitive to comparable transactions. Biomed
Solutions is headed by Biophan CEO Michael Weiner, who is also a substantial
beneficial owner of Biomed Solutions. The balance of borrowings on the line was
$4,430,000 at May 31, 2006.
In addition, on May 27, 2005, we entered into a Line of Credit Agreement with
Biomed, whereby Biomed agreed to provide a line of credit facility of up to $2
million. Borrowings under the line bear interest at 8% per annum, are payable on
demand after August 31, 2006 and are convertible, at Biomed's election into the
Company's common stock at 90% of the average closing price for the 20 trading
days preceding the date of borrowings under the line. In June 2005, the Company
borrowed the entire $2 million under the line in two separate draws of $1
million each, in accordance with the agreement. On August 31, 2005, Biomed
elected to convert $1 million of the note plus accrued interest into 480,899
shares of common stock at which time, the remaining discount related to the $1
million portion of the loan was fully expensed. On October 7, 2005, we repaid
$500,000 of principal and all accrued interest on the loan. The balance of
borrowings on the line was $500,000 at May 31, 2006.
As described in greater detail under the heading "Stockholders' Equity" in the
"Notes to Condensed Consolidated Financial Statements", we have a current
financing agreement with SBI Brightline XI, LLC for a $30 million fixed price
financing for up to 10,000,000 shares at prices ranging from $2 to $4 a share.
The sales of stock must be taken in sequential traunches of 1 million shares
each and the financing agreement requires the shares to be registered for sale
by SBI. Registration of the shares for resale by SBI was effective on May 23,
2006 and the Company elected to sell the first traunche of 1 million shares at
$2 per share on May 23, 2006. The funds from the sale of this first traunches
have been received.
We anticipate the next sale of 1,000,000 shares of common stock to SBI
Brightline XI, LLC in the second fiscal quarter of 2007 and we plan to use this
capital on an as needed basis to fund operations. Additionally, certain
negotiations in process with several medical device companies may generate
additional working capital in the form of up-front licensing fees and/or royalty
advances.
Effective November 30, 2005, we entered into a Securities Purchase Agreement
with Myotech, LLC to acquire a substantial minority interest in Myotech, LLC
with the right to acquire a controlling interest. The acquisition involved
approximately $11.1 million of newly issued shares of our common stock and cash
advances in exchange for Class A units in Myotech, LLC.
13
The independent members of our Board of Directors negotiated, recommended and
approved all terms of this transaction. Our Board of Directors, including the
independent members, determined that the transaction was in the best interests
of Biophan's stockholders.
Based upon the terms of the Securities Purchase Agreement, we are obligated to
purchase for cash consideration of $2.225 million an additional 811,037 Class A
units. We may elect to acquire up to an additional 3,563,097 Class A units for a
further cash consideration of up to $9.775 million, over a 24-month period,
which may result in the Company owning a majority interest in Myotech.
Alternatively, the Company has the right to terminate further investment under
provisions of the stock purchase agreement.
During the three month period ended May 31, 2006, Biophan has provided $0.675
million of additional funding, for a total of $1.860 million toward the cash
consideration of $2.225 million cited above, for 677,991 Class A units of
Myotech, which increased our ownership to 41.6%. Biophan has also provided an
additional amount of funding since May 31, 2006 of $250,000, increasing our
ownership to 42.0%.
We believe that funding available under the SBI stock purchase agreement, the
Biomed lines of credit, and the Boston Scientific investment will provide the
Company with adequate working capital resources for the upcoming 12 months of
operations including the ability to fund, as needed, potential additional
acquisitions and expansion of operations.
RESULTS OF OPERATIONS
The following comments discuss the significant factors affecting the
consolidated operating results, financial condition and liquidity and cash flows
of the Company for the three months ended May 31, 2006 as compared to the three
months ended May 31, 2005.
COMPARISON OF THE THREE MONTHS ENDED MAY 31, 2006 AND 2005
REVENUES
Revenues were $0.345 million for the three months ended May 31, 2006 as
compared to no revenues for the three months ended May 31, 2005. The increase is
due to development contract payments and license fees from Boston Scientific
Scimed, and operating revenues from our European subsidiary, which consisted
primarily of MRI-related testing and consulting services to medical device
manufacturers.
OPERATING EXPENSES
Research and Development. Research and development expenses decreased by
3.6%, to approximately $1.54 million for the three months ended May 31, 2006
from approximately $1.6 million for the three months ended May 31, 2005. Stock
options expense (non cash expense) amounted to $0.278 million in the three
months ended May 31, 2006 under FAS 123R and $0.794 million in the three months
ended May 31, 2005 due primarily to the accounting for contingent stock options.
Without consideration for expenses related to stock options, the expense for the
three months ended May 31, 2006 would have been $1.265 million compared to $.806
million for the same period in 2005, or an increase of $.459 million, or 57%.
This increase is primarily attributable to increased spending on several
research and development projects of $0.350 million, increased spending of
$0.175 million in Biophan Europe, increased salaries of $0.067 million, and
reduced outside services of $0.142 million.
General and Administrative. General and administrative expenses increased
by 2% to approximately $1.93 million for the three months ended May 31, 2006
from approximately $1.90 million for the three months ended May 31, 2005. Stock
options expense (non cash expense) amounted to $0.303 million in the three
months ended May 31, 2006 under FAS 123R and $0.668 million in the three months
ended May 31, 2005 due primarily to the accounting for contingent stock options.
Without consideration for expenses related to stock options, the expense for the
three months ended May 31, 2006 would have been $1.594 million compared to
$1.102 million, or an increase of $0.491 million, or 45% over the same period in
2005. This increase is primarily attributable to increased spending for legal
services of $0.204 million, outside financial compliance and audit services of
$0.153 million, staffing additions of $0.155 million, increased salaries of
$0.040 million, combined with reduced public relations expenses by $0.113
million.
14
OTHER INCOME (EXPENSE)
Interest Expense. We incurred interest expense amounting to approximately
$0.303 million for the three months ended May 31, 2006 compared to no expense
for the three months ended May 31, 2005. The expense pertained to a $5 million
line of credit from Biomed Solutions, LLC ("Biomed"). This borrowing included a
beneficial conversion feature of $0.209 million (non cash expense) and normal
interest expense of $0.094 million.
Equity Loss on Investment. This loss is a pro rata share of the loss
incurred by Myotech, LLC for the three months ended May 31, 2006. There was no
investment in Myotech LLC or loss on investment in Myotech LLC for the three
months ended May 31, 2005. As further described under the heading "Investment in
Myotech LLC" in the "Notes to Condensed Consolidated Financial Statements" the
Company holds a 41.6% minority interest in Myotech LLC, valued on our balance
sheet at May 31, 2006 at $12.107 million.
CAPITAL RESOURCES
Our current strategic plan does not indicate a need for material capital
expenditures in the conduct of research and development activities.
We currently employ twenty-three full-time individuals, eighteen in the U.S. and
five in Europe.
FORWARD LOOKING STATEMENTS
Forward looking statements in this Form 10-Q and in other documents incorporated
herein, as well as in oral statements made by the Company, statements that are
prefaced with the words "may," "will," "expect," "anticipate," "continue,"
"estimate," "project," "intend," "designed" and similar expressions, are
intended to identify forward-looking statements regarding events, conditions,
and financial trends that may affect the Company's future plans of operations,
business strategy, results of operations and financial position. These
statements are based on the Company's current expectations and estimates as to
prospective events and circumstances about which the Company can give no firm
assurance. Further, any forward-looking statement speaks only as of the date on
which such statement is made, and the Company undertakes no obligation to update
any forward-looking statement to reflect subsequent events or circumstances.
Forward-looking statements should not be relied upon as a prediction of actual
future financial condition or results. These forward-looking statements, like
any forward-looking statements, involve risks and uncertainties that could cause
actual results to differ materially from those projected or unanticipated.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Derivative Financial Instruments, Other Financial Instruments, and Derivative
Commodity Instruments.
As of May 31, 2006, the Company did not participate in any derivative financial
instruments, or other financial and commodity instruments for which fair value
disclosure would be required under SFAS No. 107.
Primary Market Risk Exposures.
The Company's primary market risk exposures are in the areas of interest rate
risk and foreign currency exchange rate risk. The Company's investment portfolio
of cash equivalents is subject to interest rate fluctuations, but the Company
believes this risk is immaterial due to the short-term nature of these
investments. For the three months ended May 31, 2006, foreign currency
translation gains were approximately $300 as a result of consolidating the
Company's foreign subsidiaries. During the period, the Company did not engage in
any foreign currency hedging activities.
ITEM 4. CONTROLS AND PROCEDURES
Based on their evaluation as of the end of the period covered by this quarterly
report on Form 10-Q, our principal executive officer and principal financial
officer, with the participation and assistance of our management, concluded that
our disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated
under the Securities Exchange Act of 1934, were effective in design and
operation. There have been no changes in our system of internal control over
financial reporting in connection with the evaluation by our principal executive
officer and principal financial officer during our fiscal quarter ended May 31,
2006 that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.
15
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are not a party to any material legal proceedings and there are no material
legal proceedings pending with respect to our property, except as noted below.
We are not aware of any legal proceedings contemplated by any governmental
authorities involving either us or our property. None of our directors, officers
or affiliates is an adverse party in any legal proceedings involving us or our
subsidiaries, or has an interest in any proceeding which is adverse to us or our
subsidiaries.
The Company is pursuing legal claims against one of its former law firms and
certain of its attorneys. Review of the firm's work product and bills recently
revealed questions about the firm's billing practices and other activities. The
amount of potential damages has not yet been quantified. Also, the law firm has
asserted claims seeking payment of additional legal fees, which claims the
Company has denied. The litigation is in an early stage. While, as with any
legal proceedings, no assurance can be given as to ultimate outcome, management
believes that the outcome of the litigation will not have a material adverse
effect upon the Company's financial condition.
ITEM 1A. RISK FACTORS
There are no material changes from risk factors as previously disclosed in the
Company's Form 10-K/A for the fiscal year ended February 28, 2006.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On May 23, 2006, we issued and sold to SBI Brightline XI, LLC ("SBI") 1,000,000
shares of our Common Stock, at a price of $2.00 per share (or $2,000,000 in the
aggregate). The purchase price represented a premium of $0.73 per share (or
approximately 57.5%) over the $1.27 per share closing price of our Common Stock
on the over-the-counter market on the date of sale.
We intend to use the proceeds from this sale of shares for general operating
expenses, including the funding of ongoing research and development efforts.
The sale was made pursuant to the Stock Purchase Agreement dated as of May 27,
2005 between us and SBI (as amended by Amendment No. 1 thereto dated January 9,
2006, the "Stock Purchase Agreement"). The shares sold on May 23 constitute the
first of ten traunches of shares which we may require SBI to purchase under the
Stock Purchase Agreement. Each traunche consists of 1,000,000 shares and may be
sold to SBI at any time, in our sole discretion. The shares in the various
traunches are issuable at increasing prices, ranging from $2.00 to $4.00 per
share. If the Stock Purchase Agreement facility is fully utilized, we would
receive aggregate proceeds of $30,000,000, at an average price of $3 per share.
The issuance and sale of the shares was made without registration under the
Securities Act of 1933 in reliance on the exemption for private placements not
involving a public offering provided in Section 4(2) thereof.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Not applicable
16
ITEM 5. OTHER INFORMATION
Not applicable.
ITEM 6. EXHIBITS
Exhibit No. Exhibit Description Location
----------- ------------------------------------------------- -------------
31.1 Certification of C.E.O. pursuant to Rule 13a-14(a) Filed herewith
31.2 Certification of C.F.O. pursuant to Rule 13a-14(a) Filed herewith
32.1 Certification of C.E.O. pursuant to Rule 13a-14(b) Filed herewith
and 18 U.S.C. Section 1350
32.2 Certification of C.F.O. pursuant to Rule 13a-14(b) Filed herewith
and 18 U.S.C. Section 1350
17
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BIOPHAN TECHNOLOGIES, INC.
(Registrant)
By: /s/ Michael L. Weiner
-------------------------------------
Name: Michael L. Weiner,
Title: Chief Executive Officer
By: /s/ Darryl L. Canfield
-------------------------------------
Name: Darryl L. Canfield
Title: Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer and Principal Accounting Officer)
Date: July 10, 2006
18